Agnew R A, Walker D J, Phillips L A
Clin Allergy. 1977 Mar;7(2):183-8. doi: 10.1111/j.1365-2222.1977.tb01440.x.
A prospective study of forty adult asthmatic patients attending two chest clinics in the City of Liverpool was undertaken. All patients had reversible airways obstruction and were under treatment with either beclomethasone dipropionate or sodium cromoglycate. Satisfactory symptomatic control was achieved in both groups of patients on a subjective basis, but there was a statistically significant (P less than 0-001) reduction in the number of admissions to hospital in the treatment year compared to the preceding 12 months in the beclomethasone aerosol group. No increased incidence of lower respiratory tract infections or non-specific sore throats was found in either group studied. No cases of clinical oral Candida infection occurred in the beclomethasone aerosol treated patients. It is concluded that beclomethasone dipropionate in aerosol form is not only a safe and effective method for symptomatic control of adult bronchial asthma but is also economically worthwhile as a means of reducing hospital admissions in this vulnerable group of patients.
对利物浦市两家胸科诊所的40名成年哮喘患者进行了一项前瞻性研究。所有患者均有可逆性气道阻塞,且正在接受二丙酸倍氯米松或色甘酸钠治疗。两组患者在主观上都取得了令人满意的症状控制,但与前12个月相比,二丙酸倍氯米松气雾剂组在治疗年度的住院人数有统计学意义的显著减少(P小于0.001)。在研究的两组中均未发现下呼吸道感染或非特异性喉咙痛的发生率增加。接受二丙酸倍氯米松气雾剂治疗的患者未发生临床口腔念珠菌感染病例。结论是,气雾剂形式的二丙酸倍氯米松不仅是一种安全有效的控制成人支气管哮喘症状的方法,而且作为减少这一脆弱患者群体住院人数的手段,在经济上也是值得的。